Simplifying the human serum proteome for discriminating patients with bipolar disorder of other psychiatry conditions

• Published in: Clinical biochemistry Vol. 50; no. 18; pp. 1118 - 1125
• Main Authors: de Jesus, Jemmyson Romário, Galazzi, Rodrigo Moretto, de Lima, Tatiani Brenelli, Banzato, Cláudio Eduardo Muller, de Almeida Lima e Silva, Luiz Fernando, de Rosalmeida Dantas, Clarissa, Gozzo, Fábio Cézar, Arruda, Marco Aurélio Zezzi
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.12.2017
• ISSN: 0009-9120; 1873-2933; 1873-2933
• DOI: 10.1016/j.clinbiochem.2017.06.009

An exploratory analysis using proteomic strategies in blood serum of patients with bipolar disorder (BD), and with other psychiatric conditions such as Schizophrenia (SCZ), can provide a better understanding of this disorder, as well as their discrimination based on their proteomic profile. The proteomic profile of blood serum samples obtained from patients with BD using lithium or other drugs (N=14), healthy controls, including non-family (HCNF; N=3) and family (HCF; N=9), patients with schizophrenia (SCZ; N=23), and patients using lithium for other psychiatric conditions (OD; N=4) were compared. Four methods for simplifying the serum samples proteome were evaluated for both removing the most abundant proteins and for enriching those of lower-abundance: protein depletion with acetonitrile (ACN), dithiothreitol (DTT), sequential depletion using DTT and ACN, and protein equalization using commercial ProteoMiner® kit (PM). For proteomic evaluation, 2-D DIGE and nanoLC-MS/MS analysis were employed. PM method was the best strategy for removing proteins of high abundance. Through 2-D DIGE gel image comparison, 37 protein spots were found differentially abundant (p<0.05, Student's t-test), which exhibited ≥2.0-fold change of the average value of normalized spot intensities in the serum of SCZ, BD and OD patients compared to subject controls (HCF and HCNF). From these spots detected, 13 different proteins were identified: ApoA1, ApoE, ApoC3, ApoA4, Samp, SerpinA1, TTR, IgK, Alb, VTN, TR, C4A and C4B. Proteomic analysis allowed the discrimination of patients with BD from patients with other mental disorders, such as SCZ. The findings in this exploratory study may also contribute for better understanding the pathophysiology of these disorders and finding potential serum biomarkers for these conditions. •DTT, ACN, DTT+ACN, or ProteoMiner® were evaluated for depleting/enriching proteins in serum samples.•ProteoMiner® is prone to be used.•37 protein spots differently found•Differentiation between bipolar and schizophrenic patients